{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:05:50Z","timestamp":1791353150805,"version":"4.3.1"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40265-018-0980-9","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T16:40:51Z","timestamp":1536684051000},"page":"1459-1479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Assessing and Treating Chronic Pain in Patients with End-Stage Renal Disease"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7184-5519","authenticated-orcid":false,"given":"Flaminia","family":"Coluzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"issue":"7","key":"980_CR1","doi-asserted-by":"crossref","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.","journal-title":"PLoS One"},{"key":"980_CR2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/j.ajkd.2003.08.025","volume":"42","author":"SN Davison","year":"2003","unstructured":"Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003;42:1239\u201347.","journal-title":"Am J Kidney Dis"},{"key":"980_CR3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4997\/JRCPE.2014.309","volume":"44","author":"CA Douglas","year":"2014","unstructured":"Douglas CA. Palliative care for patients with advanced chronic kidney disease. J R Coll Physicians Edinb. 2014;44:224\u201331.","journal-title":"J R Coll Physicians Edinb"},{"key":"980_CR4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.ackd.2006.10.001","volume":"14","author":"FE Murtagh","year":"2007","unstructured":"Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14:82\u201399.","journal-title":"Adv Chronic Kidney Dis."},{"key":"980_CR5","first-page":"236","volume":"29","author":"J Calls","year":"2009","unstructured":"Calls J, Rodriguez Calero MA, Hernandez Sanchez D, Gutierrez Navarro MJ, Juan Amer F, Tura DD, et al. An evaluation of pain in haemodialysis patients using different validated measurement scales. Nefrologia. 2009;29:236\u201343.","journal-title":"Nefrologia"},{"key":"980_CR6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/sdi.12196","volume":"27","author":"SN Davison","year":"2014","unstructured":"Davison SN, Koncicki H, Brennan F. Pain\u00a0in chronic\u00a0kidney\u00a0disease: a scoping review. Semin Dial. 2014;27:188\u2013204.","journal-title":"Semin Dial"},{"key":"980_CR7","first-page":"1131","volume":"10","author":"T Brkovic","year":"2016","unstructured":"Brkovic T, Burilovic E, Puljak L. Prevalence and severity of pain in adult end-stage renal disease patients on chronic intermittent hemodialysis: a systematic review. Patient Prefer Adherence. 2016;10:1131\u201350.","journal-title":"Patient Prefer Adherence."},{"key":"980_CR8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/papr.12594","volume":"18","author":"T Brkovic","year":"2018","unstructured":"Brkovic T, Burilovic E, Puljak L. Risk\u00a0factors associated with pain on chronic intermittent hemodialysis: a systematic review. Pain Pract. 2018;18:247\u201368.","journal-title":"Pain Pract."},{"key":"980_CR9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2369-15-6","volume":"15","author":"HJ Hsu","year":"2014","unstructured":"Hsu HJ, Yen CH, Hsu KH, Wu IW, Lee CC, Hung MJ, et al. Factors associated with chronic musculoskeletal pain in patients with chronic kidney disease. BMC Nephrol. 2014;15:6.","journal-title":"BMC Nephrol."},{"key":"980_CR10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jpainsymman.2009.08.008","volume":"39","author":"SN Davison","year":"2010","unstructured":"Davison SN, Jhangri GS. Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. J Pain Symptom Manag. 2010;39:477\u201385.","journal-title":"J Pain Symptom Manag"},{"key":"980_CR11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2215\/CJN.00220114","volume":"9","author":"SD Weisbord","year":"2014","unstructured":"Weisbord SD, Mor MK, Sevick MA, Shields AM, Rollman BL, Palevsky PM, et al. Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis. Clin J Am Soc Nephrol. 2014;9:1594\u2013602.","journal-title":"Clin J Am Soc Nephrol"},{"key":"980_CR12","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2174\/1381612054864993","volume":"11","author":"F Coluzzi","year":"2005","unstructured":"Coluzzi F, Mattia C. Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des. 2005;11:2945\u201360.","journal-title":"Curr Pharm Des"},{"key":"980_CR13","first-page":"1672","volume":"21","author":"F Coluzzi","year":"2017","unstructured":"Coluzzi F, Fornasari D, Pergolizzi J, Romualdi P. From acute to chronic pain: tapentadol in the progressive stages of this disease entity. Eur Rev Med Pharmacol Sci. 2017;21:1672\u201383.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"980_CR14","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/03007995.2017.1298521","volume":"33","author":"G M\u00fcller-Schwefe","year":"2017","unstructured":"M\u00fcller-Schwefe G, Morlion B, Ahlbeck K, Alon E, Coaccioli S, Coluzzi F, et al. Treatment for chronic low back pain: the focus should change to multimodal management that reflects the underlying pain mechanisms. Curr Med Res Opin. 2017;33:1199\u2013210.","journal-title":"Curr Med Res Opin"},{"key":"980_CR15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ejp.1140","volume":"22","author":"L Arendt-Nielsen","year":"2018","unstructured":"Arendt-Nielsen L, Morlion B, Perrot S, Dahan A, Dickenson A, Kress HG, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018;22:216\u201341.","journal-title":"Eur J Pain"},{"key":"980_CR16","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1185\/03007995.2014.887005","volume":"30","author":"HG Kress","year":"2014","unstructured":"Kress HG, Ahlbeck K, Aldington D, Alon E, Coaccioli S, Coluzzi F, et al. Managing chronic pain in elderly patients requires a CHANGE of approach. Curr Med Res Opin. 2014;30:1153\u201364.","journal-title":"Curr Med Res Opin"},{"key":"980_CR17","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.juro.2014.10.124","volume":"193","author":"MW Tellman","year":"2015","unstructured":"Tellman MW, Bahler CD, Shumate AM, Bacallao RL, Sundaram CP. Management of pain in autosomal dominant polycystic kidney disease and anatomy of renal innervation. J Urol. 2015;193:1470\u20138.","journal-title":"J Urol"},{"key":"980_CR18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/IJNRD.S84784","volume":"9","author":"R Scarpioni","year":"2016","unstructured":"Scarpioni R, Ricardi M, Albertazzi V, De Amicis S, Rastelli F, Zerbini L. Dialysis-related\u00a0amyloidosis: challenges and solutions. Int J Nephrol Renovasc Dis. 2016;9:319\u201328.","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"980_CR19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.ajkd.2015.01.034","volume":"66","author":"SU Nigwekar","year":"2015","unstructured":"Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66:133\u201346.","journal-title":"Am J Kidney Dis"},{"key":"980_CR20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/ner.12753","volume":"21","author":"JT Liu","year":"2018","unstructured":"Liu JT, Su CH, Chen SY, Liew SJ, Chang CS. Spinal Cord Stimulation improves the microvascular perfusion insufficiency caused by critical limb\u00a0ischemia. Neuromodulation. 2018;21:489\u201394.","journal-title":"Neuromodulation."},{"key":"980_CR21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/sdi.12372","volume":"28","author":"HM Koncicki","year":"2015","unstructured":"Koncicki HM, Brennan F, Vinen K, Davison SN. An approach to pain management in end stage renal disease: considerations for general management and intradialytic symptoms. Semin Dial. 2015;28:384\u201391.","journal-title":"Semin Dial"},{"key":"980_CR22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.15537\/smj.2015.2.10036","volume":"36","author":"SO Wali","year":"2015","unstructured":"Wali SO, Alkhouli AF. Restless legs syndrome\u00a0among Saudi\u00a0end-stage renal disease\u00a0patients on hemodialysis. Saudi Med J. 2015;36:204\u201310.","journal-title":"Saudi Med J"},{"key":"980_CR23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.sleep.2014.05.011","volume":"15","author":"DL Bliwise","year":"2014","unstructured":"Bliwise DL, Zhang RH, Kutner NG. Medications associated with\u00a0restless legs syndrome: a case control study in the US\u00a0renal\u00a0data system (USRDS). Sleep Med. 2014;15:1241\u20135.","journal-title":"Sleep Med"},{"key":"980_CR24","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.clinph.2013.04.012","volume":"124","author":"R Arnold","year":"2013","unstructured":"Arnold R, Kwai NC, Krishnan AV. Mechanisms of axonal dysfunction in\u00a0diabetic\u00a0and uraemic\u00a0neuropathies. Clin Neurophysiol. 2013;124:2079\u201390.","journal-title":"Clin Neurophysiol"},{"key":"980_CR25","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ndt\/gfv114","volume":"30","author":"MR Kaminski","year":"2015","unstructured":"Kaminski MR, Raspovic A, McMahon LP, Strippoli GF, Palmer SC, Ruospo M, et al. Risk factors for foot ulceration and lower extremity amputation in adults with end-stage\u00a0renal\u00a0disease on\u00a0dialysis: a systematic\u00a0review\u00a0and meta-analysis. Nephrol Dial Transplant. 2015;30:1747\u201366.","journal-title":"Nephrol Dial Transplant"},{"key":"980_CR26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5527\/wjn.v7.i2.58","volume":"7","author":"TY Yong","year":"2018","unstructured":"Yong TY, Khow KSF. Diabetic muscle infarction in end-stage\u00a0renal\u00a0disease: a scoping\u00a0review\u00a0on epidemiology, diagnosis and treatment. World J Nephrol. 2018;7:58\u201364.","journal-title":"World J Nephrol."},{"key":"980_CR27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5414\/CN107917","volume":"80","author":"E Aitken","year":"2013","unstructured":"Aitken E, McLellan A, Glen J, Serpell M, Mactier R, Clancy M. Pain resulting from arteriovenous fistulae: prevalence and impact. Clin Nephrol. 2013;80:328\u201333.","journal-title":"Clin Nephrol"},{"key":"980_CR28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1468-2982.2004.00668.x","volume":"24","author":"B G\u00f6ksan","year":"2004","unstructured":"G\u00f6ksan B, Karaali-Savrun F, Ertan S, Savrun M. Hemodialysis- related headache. Cephalagia. 2004;24:284\u20137.","journal-title":"Hemodialysis- related headache. Cephalagia"},{"key":"980_CR29","doi-asserted-by":"crossref","unstructured":"Ballinger AE, Palmer SC, Wiggins KJ, Craig JC, Johnson DW, Cross NB, et al. Treatment for\u00a0peritoneal\u00a0dialysis-associated peritonitis. Cochrane Database Syst Rev. 2014;(4):CD005284.","DOI":"10.1002\/14651858.CD005284.pub3"},{"key":"980_CR30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/BMR-130375","volume":"26","author":"F Soyupek","year":"2013","unstructured":"Soyupek F, Demir M, S\u00fcsl\u00fc FE, Baykal B, Sezer MT, Yesildag A. The upper extremity musculoskeletal complications in\u00a0dialysis\u00a0patients: comparison between hemodialysis and\u00a0peritoneal dialysis. J Back Musculoskelet Rehabil. 2013;26:267\u2013371.","journal-title":"J Back Musculoskelet Rehabil."},{"key":"980_CR31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0272-6386(88)80082-9","volume":"11","author":"RL Benz","year":"1988","unstructured":"Benz RL, Siegfried JW, Teehan BP. Carpal tunnel syndrome in\u00a0dialysis\u00a0patients: comparison between continuous ambulatory\u00a0peritoneal dialysis\u00a0and hemodialysis populations. Am J Kidney Dis. 1988;11:473\u20136.","journal-title":"Am J Kidney Dis"},{"key":"980_CR32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/0886022X.2014.982486","volume":"37","author":"B Stojimirovic","year":"2015","unstructured":"Stojimirovic B, Milinkovic M, Zidverc-Trajkovic J, Trbojevic-Stankovic J, Maric I, Milic M, et al. Dialysis\u00a0headache\u00a0in patients undergoing\u00a0peritoneal dialysis\u00a0and\u00a0hemodialysis. Ren Fail. 2015;37:241\u20134.","journal-title":"Ren Fail"},{"key":"980_CR33","doi-asserted-by":"crossref","first-page":"11370","DOI":"10.3748\/wjg.v20.i32.11370","volume":"20","author":"R Dong","year":"2014","unstructured":"Dong R, Guo ZY, Ding JR, Zhou YY, Wu H. Gastrointestinal symptoms: a comparison between patients undergoing\u00a0peritoneal dialysis and\u00a0hemodialysis. World J Gastroenterol. 2014;20:11370\u20135.","journal-title":"World J Gastroenterol"},{"key":"980_CR34","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2215\/CJN.01220406","volume":"1","author":"E Juergensen","year":"2006","unstructured":"Juergensen E, Wuerth D, Finkelstein SH, Juergensen PH, Bekui A, Finkelstein FO. Hemodialysis\u00a0and\u00a0peritoneal dialysis: patients\u2019 assessment of their satisfaction with therapy and the impact of the therapy on their lives. Clin J Am Soc Nephrol. 2006;1:1191\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"key":"980_CR35","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/03007995.2018.1449738","volume":"34","author":"B Morlion","year":"2018","unstructured":"Morlion B, Coluzzi F, Aldington D, Kocot-Kepska M, Pergolizzi J, Mangas AC, et al. Pain chronification: what should a non-pain medicine specialist know? Curr Med Res Opin. 2018;34:1169\u201378.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"980_CR36","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s00586-005-1044-x","volume":"15","author":"M Haefeli","year":"2006","unstructured":"Haefeli M, Elfering A. Pain assessment. Eur Spine J. 2006;15(Suppl 1):S17\u201324.","journal-title":"Eur Spine J"},{"key":"980_CR37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","volume":"1","author":"R Melzack","year":"1975","unstructured":"Melzack R. The McGill pain questionnaire: major properties and scoring methods. Pain. 1975;1:277\u201399.","journal-title":"Pain"},{"key":"980_CR38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","volume":"17","author":"RL Daut","year":"1983","unstructured":"Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197\u2013210.","journal-title":"Pain"},{"key":"980_CR39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpain.2004.11.007","volume":"6","author":"MI Bennett","year":"2005","unstructured":"Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6:149\u201358.","journal-title":"J Pain."},{"key":"980_CR40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pain.2004.12.010","volume":"114","author":"D Bouhassira","year":"2005","unstructured":"Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29\u201336.","journal-title":"Pain"},{"key":"980_CR41","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1185\/030079906X132488","volume":"22","author":"R Freynhagen","year":"2006","unstructured":"Freynhagen R, Baron R, Gockel U, T\u00f6lle TR. painDETECT: a new screening questionnaire to identify neuropathic compo- nents in patients with back pain. Curr Med Res Opin. 2006;22:1911\u201320.","journal-title":"Curr Med Res Opin"},{"key":"980_CR42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jpain.2004.11.002","volume":"6","author":"MP Jensen","year":"2005","unstructured":"Jensen MP, Dworkin RH, Gammaitoni AR, Olaleye DO, Oleka N, Galer BS. Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. J Pain. 2005;6:98\u2013106.","journal-title":"J Pain"},{"key":"980_CR43","doi-asserted-by":"crossref","unstructured":"Coluzzi F, Puleo L, Di Bussolo E, Muci ML, Mazzaferro S. Pain management in patients with end-stage renal disease undergoing hemodialysis. Abstract EFIC7-0943;10th Congress of the European Pain Federation, EFIC\u00ae 2017, Copenhagen, Denmark","DOI":"10.26226\/morressier.5992f047d462b80290b53951"},{"key":"980_CR44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jpsychores.2012.04.015","volume":"73","author":"VT Preljevic","year":"2012","unstructured":"Preljevic VT, \u00d8sthus TB, Sandvik L, Opjordsmoen S, Nordhus IH, Os I, et al. Screening for anxiety and depression in dialysis patients: comparison of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory. J Psychosom Res. 2012;73:139\u201344.","journal-title":"J Psychosom Res"},{"key":"980_CR45","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606\u201313.","journal-title":"J Gen Intern Med"},{"key":"980_CR46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5114\/aoms.2016.59765","volume":"14","author":"M Kusztal","year":"2018","unstructured":"Kusztal M, Trafid\u0142o E, Madziarska K, Augustyniak-Bartosik H, Karczewski M, Weyde W, et al. Depressive symptoms but not chronic\u00a0pain\u00a0have an impact on the survival of patients undergoing maintenance hemodialysis. Arch Med Sci. 2018;14:265\u201375.","journal-title":"Arch Med Sci."},{"key":"980_CR47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12882-018-0849-x","volume":"19","author":"ST Khatib","year":"2018","unstructured":"Khatib ST, Hemadneh MK, Hasan SA, Khazneh E, Zyoud SH. Quality of life in hemodialysis diabetic patients: a multicenter cross-sectional study from Palestine. BMC Nephrol. 2018;19:49.","journal-title":"BMC Nephrol."},{"key":"980_CR48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12882-016-0257-z","volume":"17","author":"SH Zyoud","year":"2016","unstructured":"Zyoud SH, Daraghmeh DN, Mezyed DO, Khdeir RL, Sawafta MN, Ayaseh NA, et al. Factors affecting quality of life in patients on haemodialysis: a cross-sectional study from Palestine. BMC Nephrol. 2016;17:44.","journal-title":"BMC Nephrol."},{"key":"980_CR49","first-page":"289","volume":"102","author":"F Coluzzi","year":"2011","unstructured":"Coluzzi F, Berti M. Change Pain: changing the approach to chronic pain. Minerva Med. 2011;102:289\u2013307.","journal-title":"Minerva Med"},{"key":"980_CR50","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","volume":"65","author":"RK Verbeeck","year":"2009","unstructured":"Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65:757\u201373.","journal-title":"Eur J Clin Pharmacol"},{"key":"980_CR51","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1001\/jamainternmed.2015.5441","volume":"175","author":"A Rosenberg","year":"2015","unstructured":"Rosenberg A, Agiro A, Gottlieb M, Barron J, Brady P, Liu Y, et al. Early trends among seven recommendations from the choosing wisely campaign. JAMA Intern Med. 2015;175:1913\u201320.","journal-title":"JAMA Intern Med."},{"key":"980_CR52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/ckj\/sfx080","volume":"10","author":"PC Pham","year":"2017","unstructured":"Pham PC, Khaing K, Sievers TM, Pham PM, Miller JM, Pham SV, et al. 2017 update on\u00a0pain\u00a0management in patients with chronic kidney disease. Clin Kidney J. 2017;10:688\u201397.","journal-title":"Clin Kidney J."},{"key":"980_CR53","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ackd.2005.03.004","volume":"12","author":"MS Markell","year":"2005","unstructured":"Markell MS. Potential benefits of complementary medicine modalities in patients with\u00a0chronic kidney\u00a0disease. Adv Chronic Kidney Dis. 2005;12:292\u20139.","journal-title":"Adv Chronic Kidney Dis."},{"key":"980_CR54","doi-asserted-by":"crossref","unstructured":"Kim KH, Lee MS, Kim TH, Kang JW, Choi TY, Lee JD. Acupuncture and related interventions for symptoms of\u00a0chronic\u00a0kidney\u00a0disease. Cochrane Database Syst Rev. 2016;(6):CD009440.","DOI":"10.1002\/14651858.CD009440.pub2"},{"key":"980_CR55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ejp.1168","volume":"22","author":"L Resende","year":"2018","unstructured":"Resende L, Merriwether E, Rampazo \u00c9P, Dailey D, Embree J, Deberg J, et al. Meta-analysis of\u00a0transcutaneous\u00a0electrical\u00a0nerve\u00a0stimulation\u00a0for relief of spinal\u00a0pain. Eur J Pain. 2018;22:663\u201378.","journal-title":"Eur J Pain"},{"key":"980_CR56","doi-asserted-by":"crossref","unstructured":"Walsh DM, Howe TE, Johnson MI, Sluka KA. Transcutaneous\u00a0electrical\u00a0nerve\u00a0stimulation\u00a0for acute pain. Cochrane Database Syst Rev. 2009;(2):CD006142.","DOI":"10.1002\/14651858.CD006142.pub2"},{"key":"980_CR57","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/hdi.12161","volume":"18","author":"A Koca Kutlu","year":"2014","unstructured":"Koca Kutlu A, Eren AG. Effects of\u00a0music\u00a0on complications during hemodialysis for\u00a0chronic\u00a0renal\u00a0failure patients. Hemodial Int. 2014;18:777\u201384.","journal-title":"Hemodial Int."},{"key":"980_CR58","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/jorc.12078","volume":"40","author":"F Burrai","year":"2014","unstructured":"Burrai F, Micheluzzi V, Zito MP, Pietro G, Sisti D. Effects of live saxophone\u00a0music\u00a0on physiological parameters,\u00a0pain, mood and itching levels in patients undergoing haemodialysis. J Ren Care. 2014;40:249\u201356.","journal-title":"J Ren Care."},{"key":"980_CR59","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1177\/1359105308095065","volume":"13","author":"M Pothoulaki","year":"2008","unstructured":"Pothoulaki M, Macdonald RA, Flowers P, Stamataki E, Filiopoulos V, Stamatiadis D, et al. An investigation of the effects of\u00a0music\u00a0on anxiety and\u00a0pain\u00a0perception in patients undergoing haemodialysis treatment. J Health Psychol. 2008;13:912\u201320.","journal-title":"J Health Psychol."},{"key":"980_CR60","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/ene.13103","volume":"23","author":"G Cruccu","year":"2016","unstructured":"Cruccu G, Garcia-Larrea L, Hansson P, Keindl M, Lefaucheur JP, Paulus W, et al. EAN\u00a0guidelines\u00a0on central neurostimulation therapy in chronic pain conditions. Eur J Neurol. 2016;23:1489\u201399.","journal-title":"Eur J Neurol"},{"key":"980_CR61","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.2009.135","volume":"86","author":"DC Brater","year":"2009","unstructured":"Brater DC. Drug\u00a0dosing in patients with impaired\u00a0renal\u00a0function. Clin Pharmacol Ther. 2009;86:483\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"980_CR62","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/978-0-585-36947-1_30","volume-title":"Replacement of renal function by dialysis","author":"TA Golper","year":"1996","unstructured":"Golper TA, Marx MA, Shuler C, Bennett WM. Drug dosage in dialysis patients. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester JF, editors. Replacement of renal function by dialysis. Dordrecht: Kluwer Academic Publishers; 1996. p. 750\u2013820."},{"key":"980_CR63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.7326\/0003-4819-93-1-62","volume":"93","author":"WM Bennett","year":"1980","unstructured":"Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, Golper TA, et al. Drug\u00a0therapy in\u00a0renal\u00a0failure: dosing guidelines for adults. Part I: antimicrobial agents,\u00a0analgesics. Ann Intern Med. 1980;93:62\u201389.","journal-title":"Ann Intern Med"},{"key":"980_CR64","first-page":"1487","volume":"75","author":"MY Munar","year":"2007","unstructured":"Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007;75:1487\u201396.","journal-title":"Am Fam Physician"},{"key":"980_CR65","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2215\/CJN.06520714","volume":"10","author":"J Wu","year":"2015","unstructured":"Wu J, Ginsberg JS, Zhan M, Diamantidis CJ, Chen J, Woods C, et al. Chronic pain and analgesic use in CKD: implications for patient safety. Clin J Am Soc Nephrol. 2015;10:435\u201342.","journal-title":"Clin J Am Soc Nephrol"},{"key":"980_CR66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00315495","volume":"45","author":"U Martin","year":"1993","unstructured":"Martin U, Temple RM, Winney RJ, Prescott LF. The disposition of\u00a0paracetamol\u00a0and its conjugates during multiple\u00a0dosing\u00a0in patients with end-stage\u00a0renal\u00a0failure maintained on\u00a0haemodialysis. Eur J Clin Pharmacol. 1993;45:141\u20135.","journal-title":"Eur J Clin Pharmacol"},{"key":"980_CR67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2125.1996.tb00157.x","volume":"41","author":"HS Lee","year":"1996","unstructured":"Lee HS, Ti TY, Lye WC, Khoo YM, Tan CC. Paracetamol\u00a0and its metabolites in saliva and plasma in chronic dialysis patients. Br J Clin Pharmacol. 1996;41:41\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"980_CR68","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3109\/15563650.2015.1100305","volume":"53","author":"SH Hernandez","year":"2015","unstructured":"Hernandez SH, Howland M, Schiano TD, Hoffman RS. The pharmacokinetics and extracorporeal removal of N-acetylcysteine during\u00a0renal\u00a0replacement therapies. Clin Toxicol (Phila). 2015;53:941\u20139.","journal-title":"Clin Toxicol (Phila)"},{"key":"980_CR69","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMp1314965","volume":"370","author":"NE Morden","year":"2014","unstructured":"Morden NE, Colla CH, Sequist TD, Rosenthal MB. Choosing wisely\u2014the politics and economics of labeling low-value services. N Engl J Med. 2014;370:589\u201392.","journal-title":"N Engl J Med"},{"key":"980_CR70","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/pds.3329","volume":"21","author":"CE Leonard","year":"2012","unstructured":"Leonard CE, Freeman CP, Newcomb CW, Reese PP, Herlim M, Bilker WB, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. 2012;21:1155\u201372.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"980_CR71","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12882-017-0673-8","volume":"18","author":"X Zhang","year":"2017","unstructured":"Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory\u00a0drug\u00a0induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic\u00a0review and meta-analysis. BMC Nephrol. 2017;18:256.","journal-title":"BMC Nephrol."},{"key":"980_CR72","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/clpt.1985.43","volume":"37","author":"CP Swainson","year":"1985","unstructured":"Swainson CP, Griffiths P. Acute and chronic effects of sulindac on renal function in chronic renal disease. Clin Pharmacol Ther. 1985;37:298\u2013300.","journal-title":"Clin Pharmacol Ther"},{"key":"980_CR73","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/j.1552-4604.1993.tb04699.x","volume":"33","author":"WR Ravis","year":"1993","unstructured":"Ravis WR, Diskin CJ, Campagna KD, Clark CR, McMillian CL. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. J Clin Pharmacol. 1993;33:527\u201334.","journal-title":"J Clin Pharmacol"},{"key":"980_CR74","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00563009","volume":"18","author":"M Anttila","year":"1980","unstructured":"Anttila M, Haataja M, Kasanen A. Pharmacokinetics of naproxen in subjects with normal and impaired renal function. Eur J Clin Pharmacol. 1980;18:263\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"980_CR75","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.1982.146","volume":"32","author":"GR Aronoff","year":"1982","unstructured":"Aronoff GR, Ozawa T, DeSante KA, Nash JF, Ridolfo AS. Benoxaprofen kinetics in renal impairment. Clin Pharmacol Ther. 1982;32:190\u20134.","journal-title":"Clin Pharmacol Ther"},{"key":"980_CR76","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1365-2125.1999.00046.x","volume":"48","author":"NG Grubb","year":"1999","unstructured":"Grubb NG, Rudy DW, Brater DC, Hall SD. Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a \u2018futile cycle\u2019 of elimination. Br J Clin Pharmacol. 1999;48:494\u2013500.","journal-title":"Br J Clin Pharmacol"},{"key":"980_CR77","doi-asserted-by":"crossref","unstructured":"al-Ghamdi MS, al-Mohanna FA, al-Mustafa ZH, al-Saeed IS. The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. Eur J Clin Pharmacol. 1992;43:197\u20139.","DOI":"10.1007\/BF01740671"},{"key":"980_CR78","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","volume":"38","author":"NM Davies","year":"2000","unstructured":"Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38:225\u201342.","journal-title":"Clin Pharmacokinet."},{"key":"980_CR79","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00045391-200307000-00004","volume":"10","author":"K Gottesdiener","year":"2003","unstructured":"Gottesdiener K, Agrawal N, Porras A, Wong P, Rogers JD, Gertz BJ, et al. Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib. Am J Ther. 2003;10:252\u20138.","journal-title":"Am J Ther."},{"key":"980_CR80","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40620-016-0352-z","volume":"30","author":"Z Heleniak","year":"2017","unstructured":"Heleniak Z, Ciepli\u0144ska M, Szychli\u0144ski T, Rychter D, Jagodzi\u0144ska K, K\u0142os A, et al. Nonsteroidal anti-inflammatory drug use in patients with chronic kidney disease. J Nephrol. 2017;30:781\u20136.","journal-title":"J Nephrol."},{"key":"980_CR81","doi-asserted-by":"crossref","unstructured":"Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long\u2010term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;(1):CD006605.","DOI":"10.1002\/14651858.CD006605.pub2"},{"key":"980_CR82","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1213\/ANE.0000000000002403","volume":"125","author":"CD Soelberg","year":"2017","unstructured":"Soelberg CD, Brown RE Jr, Du Vivier D, Meyer JE, Ramachandran BK. The US\u00a0opioid\u00a0crisis: current federal and state legal issues. Anesth Analg. 2017;125:1675\u201381.","journal-title":"Anesth Analg"},{"key":"980_CR83","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC\u00a0guideline\u00a0for\u00a0prescribing\u00a0opioids\u00a0for chronic pain: United States, 2016. JAMA. 2016;315:1624\u201345.","journal-title":"JAMA"},{"key":"980_CR84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ejp.970","volume":"21","author":"T O\u2019Brien","year":"2017","unstructured":"O\u2019Brien T, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ, et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21:3\u201319.","journal-title":"Eur J Pain"},{"key":"980_CR85","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.23736\/S0375-9393.17.12269-8","volume":"83","author":"F Coluzzi","year":"2017","unstructured":"Coluzzi F. \u201cI am in pain\u201d: is it really the magic formula to open the door of opioid abuse? Minerva Anestesiol. 2017;83:1332\u20133.","journal-title":"Minerva Anestesiol"},{"key":"980_CR86","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0272-6386(03)00645-0","volume":"42","author":"M Kurella","year":"2003","unstructured":"Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis. 2003;42:217\u201328.","journal-title":"Am J Kidney Dis"},{"key":"980_CR87","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2215\/CJN.04770610","volume":"6","author":"A Wyne","year":"2011","unstructured":"Wyne A, Rai R, Cuerden M, Clark WF, Suri RS. Opioid and benzodiazepine use in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol. 2011;6:326\u201333.","journal-title":"Clin J Am Soc Nephrol"},{"key":"980_CR88","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/j.ajkd.2015.07.029","volume":"66","author":"RE Olivo","year":"2015","unstructured":"Olivo RE, Hensley RL, Lewis JB, Saha S. Opioid use in hemodialysis patients. Am J Kidney Dis. 2015;66:1103\u20135.","journal-title":"Am J Kidney Dis"},{"key":"980_CR89","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1681\/ASN.2017010098","volume":"28","author":"PL Kimmel","year":"2017","unstructured":"Kimmel PL, Fwu CW, Abbott KC, Eggers AW, Kline PP, Eggers PW. Opioid prescription, morbidity, and mortality in United States dialysis patients. J Am Soc Nephrol. 2017;28:3658\u201370.","journal-title":"J Am Soc Nephrol"},{"key":"980_CR90","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2215\/CJN.09910917","volume":"13","author":"JH Ishida","year":"2018","unstructured":"Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Opioid analgesics and adverse outcomes among hemodialysis patients. Clin J Am Soc Nephrol. 2018;13:746\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"980_CR91","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/j.ajkd.2013.09.008","volume":"63","author":"AM Butler","year":"2014","unstructured":"Butler AM, Kshirsagar AV, Brookhart MA. Opioid use in the US hemodialysis population. Am J Kidney Dis. 2014;63:171\u20133.","journal-title":"Am J Kidney Dis"},{"key":"980_CR92","first-page":"e222","volume":"21","author":"DM Kern","year":"2015","unstructured":"Kern DM, Zhou S, Chavoshi S, Tunceli O, Sostek M, Singer J, et al. Treatment patterns, healthcare utilization, and costs of chronic opioid treatment for non-cancer pain in the United States. Am J Manag Care. 2015;21:e222\u201334.","journal-title":"Am J Manag Care"},{"key":"980_CR93","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/0269216311406313","volume":"25","author":"S King","year":"2011","unstructured":"King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and\u00a0renal\u00a0impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med. 2011;25:525\u201352.","journal-title":"Palliat Med"},{"key":"980_CR94","first-page":"819","volume":"3","author":"F Coluzzi","year":"2007","unstructured":"Coluzzi F, Mattia C. Chronic non-cancer pain: Focus on once-daily\u00a0tramadol\u00a0formulations. Ther Clin Risk Manag. 2007;3:819\u201329.","journal-title":"Ther Clin Risk Manag"},{"key":"980_CR95","first-page":"369","volume":"99","author":"C Mattia","year":"2008","unstructured":"Mattia C, Coluzzi F, Sarzi Puttini P, Vigan\u00f3 R. Paracetamol\/Tramadol\u00a0association: the easy solution for mild-moderate pain. Minerva Med. 2008;99:369\u201390.","journal-title":"Minerva Med"},{"key":"980_CR96","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003495-199346020-00008","volume":"46","author":"CR Lee","year":"1993","unstructured":"Lee CR, McTavish D, Sorkin EM. Tramadol. Drugs. 1993;46:313\u201340.","journal-title":"Tramadol. Drugs"},{"key":"980_CR97","unstructured":"Tramadol ER\u2014FDA prescribing information, side effects and uses. Par Pharmaceutical, Inc. 2017. http:\/\/www.drugs.com\/pro\/tramadol-er.html ."},{"key":"980_CR98","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0304-3959(97)03350-2","volume":"71","author":"SK Barnung","year":"1997","unstructured":"Barnung SK, Treshow M, Borgbjerg FM. Respiratory depression following oral tramadol in a patient with impaired renal function. Pain. 1997;71:111\u20132.","journal-title":"Pain"},{"key":"980_CR99","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10194-004-0076-7","volume":"5","author":"C Mattia","year":"2004","unstructured":"Mattia C, Mazzaferro S, Coluzzi F, Luzi M. Respiratory depression following iatrogenic tramadol overuse in a patient with chronic renal failure. J Headache Pain. 2004;5:137\u20139.","journal-title":"J Headache Pain"},{"key":"980_CR100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.tpj.6500406","volume":"7","author":"J Kirchheiner","year":"2007","unstructured":"Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, L\u00f6tsch J, Roots I, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7:257\u201365.","journal-title":"Pharmacogenomics J."},{"key":"980_CR101","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00228-009-0759-8","volume":"66","author":"H Molanaei","year":"2010","unstructured":"Molanaei H, Carrero JJ, Heimb\u00fcrger O, Nordfors L, Lindholm B, Stenvinkel P, et al. Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. Eur J Clin Pharmacol. 2010;66:269\u201373.","journal-title":"Eur J Clin Pharmacol"},{"key":"980_CR102","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jpainsymman.2004.02.021","volume":"28","author":"M Dean","year":"2004","unstructured":"Dean M. Opioids in\u00a0renal\u00a0failure and\u00a0dialysis\u00a0patients. J Pain Symptom Manag. 2004;28:497\u2013504.","journal-title":"J Pain Symptom Manag"},{"key":"980_CR103","first-page":"507","volume":"19","author":"C Mattia","year":"2015","unstructured":"Mattia C, Coluzzi F. A look inside the association\u00a0codeine-paracetamol: clinical pharmacology supports analgesic efficacy. Eur Rev Med Pharmacol Sci. 2015;19:507\u201316.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"980_CR104","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/000992289703600308","volume":"36","author":"GA Talbott","year":"1997","unstructured":"Talbott GA, Lynn AM, Levy FH, Zelikovic I. Respiratory arrest precipitated by codeine in a child with chronic renal failure. Clin Pediatr (Phila). 1997;36:171\u20133.","journal-title":"Clin Pediatr (Phila)."},{"key":"980_CR105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00520-016-3447-0","volume":"25","author":"TA Sande","year":"2017","unstructured":"Sande TA, Laird BJ, Fallon MT. The use of opioids in cancer patients with renal impairment-a systematic review. Support Care Cancer. 2017;25:661\u201375.","journal-title":"Support Care Cancer"},{"key":"980_CR106","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/RHU.0b013e31819b9610","volume":"15","author":"R Joshi","year":"2009","unstructured":"Joshi R, Reen B, Sheehan H. Upper extremity diabetic muscle infarction in three patients with endstage renal disease: a case series and review. J Clin Rheumatol. 2009;15:81\u20134.","journal-title":"J Clin Rheumatol."},{"key":"980_CR107","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2146\/ajhp150748","volume":"73","author":"J Han","year":"2016","unstructured":"Han J, Saraf SL, Gordeuk VR, Gowhari M. Safety of chronic transdermal\u00a0fentanyl\u00a0use in patients receiving hemodialysis. Am J Health Syst Pharm. 2016;73:947\u20138.","journal-title":"Am J Health Syst Pharm"},{"key":"980_CR108","first-page":"451","volume":"71","author":"F Coluzzi","year":"2005","unstructured":"Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol. 2005;71:451\u201360.","journal-title":"Minerva Anestesiol"},{"key":"980_CR109","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/papr.12483","volume":"17","author":"BG Samolsky Dekel","year":"2017","unstructured":"Samolsky Dekel BG, Donati G, Vasarri A, Croci Chiocchini AL, Gori A, Cavallari G, et al. Dialyzability of oxycodone and its metabolites in chronic noncancer pain patients with end-stage renal disease. Pain Pract. 2017;17:604\u201315.","journal-title":"Pain Pract."},{"key":"980_CR110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpainsymman.2006.09.003","volume":"33","author":"JR Hardy","year":"2007","unstructured":"Hardy JR, Herbert AR, Reymond E. Opioids in patients on renal dialysis. J Pain Symptom Manag. 2007;33:1\u20132.","journal-title":"J Pain Symptom Manag"},{"key":"980_CR111","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1191\/0269216305pm1004cr","volume":"19","author":"MA Lee","year":"2005","unstructured":"Lee MA, Leng ME, Cooper RM. Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis. Palliat Med. 2005;19:259\u201360.","journal-title":"Palliat Med"},{"key":"980_CR112","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/cpdd.238","volume":"5","author":"M Darwish","year":"2016","unstructured":"Darwish M, Yang R, Tracewell W, Robertson P Jr, Bond M. effects of renal impairment and hepatic impairment on the pharmacokinetics of hydrocodone after administration of a hydrocodone extended-release tablet formulated with abuse-deterrence technology. Clin Pharmacol Drug Dev. 2016;5:141\u20139.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"980_CR113","first-page":"1072","volume":"76","author":"F Coluzzi","year":"2010","unstructured":"Coluzzi F, Mattia C. OROS\u00ae hydromorphone in chronic pain management: when drug delivery technology matches clinical needs. Minerva Anestesiol. 2010;76:1072\u201384.","journal-title":"Minerva Anestesiol"},{"key":"980_CR114","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","volume":"10","author":"J Pergolizzi","year":"2010","unstructured":"Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428\u201350.","journal-title":"Pain Pract."},{"key":"980_CR115","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2018.1462701","author":"JV Pergolizzi Jr","year":"2018","unstructured":"Pergolizzi JV Jr, Coluzzi F, Taylor R Jr. Transdermal buprenorphine for moderate chronic noncancer pain syndromes. Expert Rev Neurother. 2018. https:\/\/doi.org\/10.1080\/14737175.2018.1462701 (epub 23 Apr 2018).","journal-title":"Expert Rev Neurother."},{"key":"980_CR116","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","volume":"10","author":"MP Davis","year":"2012","unstructured":"Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10:209\u201319.","journal-title":"J Support Oncol."},{"issue":"Suppl 1","key":"980_CR117","doi-asserted-by":"crossref","first-page":"s17","DOI":"10.1191\/0269216306pm1127oa","volume":"20","author":"RH B\u00f6ger","year":"2006","unstructured":"B\u00f6ger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med. 2006;20(Suppl 1):s17\u201323.","journal-title":"Palliat Med."},{"key":"980_CR118","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ejpain.2005.12.001","volume":"10","author":"J Filitz","year":"2006","unstructured":"Filitz J, Griessinger N, Sittl R, Likar R, Sch\u00fcttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain. 2006;10:743\u20138.","journal-title":"Eur J Pain"},{"key":"980_CR119","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11208600-000000000-00000","volume":"72","author":"SM Hoy","year":"2012","unstructured":"Hoy SM. Tapentadol extended release: in adults with chronic pain. Drugs. 2012;72:375\u201393.","journal-title":"Drugs."},{"key":"980_CR120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.ajkd.2016.08.039","volume":"69","author":"HM Koncicki","year":"2017","unstructured":"Koncicki HM, Unruh M, Schell JO. Pain management in CKD: a guide for nephrology providers. Am J Kidney Dis. 2017;69:451\u201360.","journal-title":"Am J Kidney Dis"},{"key":"980_CR121","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2165\/00003088-199631060-00002","volume":"31","author":"G Davies","year":"1996","unstructured":"Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacol Kinet. 1996;31:410\u201322.","journal-title":"Clin Pharmacol Kinet"},{"key":"980_CR122","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12871-015-0150-5","volume":"16","author":"Y Deng","year":"2016","unstructured":"Deng Y, Luo L, Hu Y, Fang K, Liu J. Clinical practice guidelines for the management of neuropathic pain: a systematic review. BMC Anesthesiol. 2016;16:12.","journal-title":"BMC Anesthesiol."},{"key":"980_CR123","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuron.2006.09.021","volume":"52","author":"JN Campbell","year":"2006","unstructured":"Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52:77\u201392.","journal-title":"Neuron"},{"key":"980_CR124","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/j.1552-4604.1995.tb05020.x","volume":"35","author":"M Wong","year":"1995","unstructured":"Wong M, Eldom M, Keane W, Turk D, Bockbrader H, Underwood B, Sedman A, Halstenson C. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol. 1995;35:622\u20136.","journal-title":"J Clin Pharmacol"},{"key":"980_CR125","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.amjmed.2009.09.030","volume":"123","author":"L Zand","year":"2010","unstructured":"Zand L, McKian K, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause or morbidity. Am J Med. 2010;123:367\u201373.","journal-title":"Am J Med"},{"key":"980_CR126","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1053\/j.ajkd.2009.04.014","volume":"54","author":"L Yoo","year":"2009","unstructured":"Yoo L, Matalon D, Hoffman RS, Goldfarb DS. Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure. Am J Kidney Dis. 2009;54:1127\u201330.","journal-title":"Am J Kidney Dis"},{"key":"980_CR127","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40261-016-0464-1","volume":"37","author":"T Otsuki","year":"2017","unstructured":"Otsuki T, Higuchi T, Yamazaki T, Okawa E, Okada K, Abe M. Efficacy and safety of pregabalin for the treatment of neuropathic pain in patients undergoing hemodialysis. Clin Drug Investig. 2017;37:95\u2013102.","journal-title":"Clin Drug Investig."},{"key":"980_CR128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ebcr.2013.12.002","volume":"2","author":"KR Kaufman","year":"2013","unstructured":"Kaufman KR, Parikh A, Chan L, Bridgeman M, Shah M. Myoclonus in renal failure: two cases of gabapentin toxicity. Epilepsy Behav Case Rep. 2013;2:8\u201310.","journal-title":"Epilepsy Behav Case Rep."},{"key":"980_CR129","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/mds.22286","volume":"24","author":"DG Healy","year":"2009","unstructured":"Healy DG, Ingle GT, Brown P. Pregabalin- and gabapentin-associated myoclonus in a patient with chronic renal failure. Mov Disord. 2009;24:2028\u20139.","journal-title":"Mov Disord"},{"key":"980_CR130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ncpneuro0806","volume":"4","author":"A Binder","year":"2008","unstructured":"Binder A, Koroschetz J, Baron R. Disease mechanisms in neuropathic itch. Nat Clin Pract Neurol. 2008;4:329\u201337.","journal-title":"Nat Clin Pract Neurol."},{"key":"980_CR131","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1440-1797.2012.01655.x","volume":"17","author":"Y Solak","year":"2012","unstructured":"Solak Y, Biyik Z, Atalay H, Gaipov A, Guney F, Turk S, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton). 2012;17:710\u20137.","journal-title":"Nephrology (Carlton)."},{"key":"980_CR132","first-page":"14","volume":"3","author":"T Lau","year":"2016","unstructured":"Lau T, Leung S, Lau W. Gabapentin for uremic pruritus in hemodialysis patients: a qualitative systematic review. Can J Kidney Health Dis. 2016;3:14.","journal-title":"Can J Kidney Health Dis."},{"key":"980_CR133","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4103\/1319-2442.168588","volume":"26","author":"SS Beladi Mousavi","year":"2015","unstructured":"Beladi Mousavi SS, Zeraati A, Moradi S, Mousavi MB. The effect of gabapentin on muscle cramps during hemodialysis: a double-blind clinical trial. Saudi J Kidney Dis Transpl. 2015;26:1142\u20138.","journal-title":"Saudi J Kidney Dis Transpl."},{"key":"980_CR134","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/0333102416687280","volume":"37","author":"S Maarbjerg","year":"2017","unstructured":"Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia\u2014diagnosis and treatment. Cephalalgia. 2017;37:648\u201357.","journal-title":"Cephalalgia"},{"key":"980_CR135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/106002808902300206","volume":"23","author":"RJ Kandrotas","year":"1989","unstructured":"Kandrotas RJ, Oles KS, Gal P, Love JM. Carbamazepine clearance in hemodialysis and hemoperfusion. DICP. 1989;23:137\u201340.","journal-title":"DICP."},{"key":"980_CR136","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3109\/15563650.2014.973572","volume":"52","author":"M Ghannoum","year":"2014","unstructured":"Ghannoum M, Yates C, Galvao TF, Sowinski KM, Vo TH, Coogan A, EXTRIP workgroup, et al. Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2014;52:993\u20131004.","journal-title":"Clin Toxicol (Phila)"},{"key":"980_CR137","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40261-016-0457-0","volume":"37","author":"SH Mahmoud","year":"2017","unstructured":"Mahmoud SH. Antiepileptic drug removal by continuous renal replacement therapy: a review of the literature. Clin Drug Investig. 2017;37:7\u201323.","journal-title":"Clin Drug Investig."},{"key":"980_CR138","first-page":"105","volume":"68","author":"C Mattia","year":"2002","unstructured":"Mattia C, Paoletti F, Coluzzi F, Boanelli A. New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol. 2002;68:105\u201314.","journal-title":"Minerva Anestesiol."},{"key":"980_CR139","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2174\/1389557033487836","volume":"3","author":"C Mattia","year":"2003","unstructured":"Mattia C, Coluzzi F. Antidepressants in chronic neuropathic pain. Mini Rev Med Chem. 2003;3:773\u201384.","journal-title":"Mini Rev Med Chem"},{"key":"980_CR140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/11319330-000000000-00000","volume":"49","author":"ED Lobo","year":"2010","unstructured":"Lobo ED, Heathman M, Kuan HY, Reddy S, O\u2019Brien L, Gonzales C, et al. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II\/III trials. Clin Pharmacokinet. 2010;49:311\u201321.","journal-title":"Clin Pharmacokinet"},{"key":"980_CR141","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/clpt.1994.95","volume":"56","author":"SM Troy","year":"1994","unstructured":"Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther. 1994;56:14\u201321.","journal-title":"Clin Pharmacol Ther"},{"key":"980_CR142","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2215\/CJN.07720716","volume":"12","author":"JE Pena-Polanco","year":"2017","unstructured":"Pena-Polanco JE, Mor MK, Tohme FA, Fine MJ, Palevsky PM, Weisbord SD. Acceptance of antidepressant treatment by patients on hemodialysis and their renal providers. Clin J Am Soc Nephrol. 2017;12:298\u2013303.","journal-title":"Clin J Am Soc Nephrol"},{"key":"980_CR143","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2147\/JPR.S125270","volume":"9","author":"RO Mathew","year":"2016","unstructured":"Mathew RO, Bettinger JJ, Wegrzyn EL, Fudin J. Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease. J Pain Res. 2016;9:1191\u20135.","journal-title":"J Pain Res."},{"key":"980_CR144","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1093\/ndt\/gfs295","volume":"27","author":"EV Nagler","year":"2012","unstructured":"Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3\u20135 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27:3736\u201345.","journal-title":"Nephrol Dial Transplant"},{"key":"980_CR145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/sdi.12370","volume":"28","author":"RF Eyler","year":"2015","unstructured":"Eyler RF, Unruh ML, Quinn DK, Vilay AM. Psychotherapeutic agents in end-stage renal disease. Semin Dial. 2015;28:417\u201326.","journal-title":"Semin Dial"},{"key":"980_CR146","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.2147\/DDDT.S142630","volume":"11","author":"G Pickering","year":"2017","unstructured":"Pickering G, Martin E, Tiberghien F, Delorme C, Mick G. Localized neuropathic pain: an expert consensus on local treatments. Drug Des Devel Ther. 2017;11:2709\u201318.","journal-title":"Drug Des Devel Ther."},{"key":"980_CR147","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jpainsymman.2016.09.015","volume":"53","author":"C Sommer","year":"2017","unstructured":"Sommer C, Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. J Pain Symptom Manag. 2017;53:614\u201329.","journal-title":"J Pain Symptom Manag"},{"key":"980_CR148","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162\u201373.","journal-title":"Lancet Neurol."},{"key":"980_CR149","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40122-016-0060-3","volume":"5","author":"R Baron","year":"2016","unstructured":"Baron R, Allegri M, Correa-Illanes G, Hans G, Serpell M, Mick G, et al. The 5% lidocaine-medicated plaster: its inclusion in international treatment guidelines for treating localized neuropathic pain, and clinical evidence supporting its use. Pain Ther. 2016;5:149\u201369.","journal-title":"Pain Ther."},{"key":"980_CR150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40122-015-0034-x","volume":"4","author":"ML Navez","year":"2015","unstructured":"Navez ML, Monella C, B\u00f6sl I, Sommer D, Delorme C. 5% lidocaine-medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability. Pain Ther. 2015;4:1\u201315.","journal-title":"Pain Ther."},{"key":"980_CR151","first-page":"297","volume":"140","author":"RF Wolff","year":"2010","unstructured":"Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine-medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140:297\u2013306.","journal-title":"Swiss Med Wkly."},{"key":"980_CR152","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jps.10133","volume":"91","author":"BJ Campbell","year":"2002","unstructured":"Campbell BJ, Rowbotham M, Davies PS, Jacob P 3rd, Benowitz NL. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002;91:1343\u201350.","journal-title":"J Pharm Sci"},{"key":"980_CR153","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/TCRM.S47138","volume":"9","author":"P Bruckenthal","year":"2013","unstructured":"Bruckenthal P, Barkin RL. Options for treating postherpetic neuralgia in the medically complicated patient. Ther Clin Risk Manag. 2013;9:329\u201340.","journal-title":"Ther Clin Risk Manag"},{"key":"980_CR154","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/15360288.2010.547561","volume":"25","author":"VM Jones","year":"2011","unstructured":"Jones VM, Moore KA, Peterson DM. Capsaicin 8% topical patch (Qutenza)\u2014a review of the evidence. J Pain Palliat Care Pharmacother. 2011;25:32\u201341.","journal-title":"J Pain Palliat Care Pharmacother."},{"key":"980_CR155","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/FTD.0b013e3181a8b200","volume":"31","author":"S Babbar","year":"2009","unstructured":"Babbar S, Marier JF, Mouksassi MS, Beliveau M, Vanhove GF, Chanda S, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31:502\u201310.","journal-title":"Ther Drug Monit"},{"key":"980_CR156","first-page":"330","volume":"18","author":"E Aitken","year":"2017","unstructured":"Aitken E, McColl G, Kingsmore D. The role of Qutenza\u00ae (topical capsaicin 8%) in treating neuropathic pain from critical ischemia in patients with end-stage renal disease: an observational cohort study. Pain Med. 2017;18:330\u201340.","journal-title":"Pain Med."},{"key":"980_CR157","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1090-3801(98)90003-9","volume":"2","author":"F Benini","year":"1998","unstructured":"Benini F, Gobber D, Lago P, Agosto C, Carli G, Zachello F. Pain management of arteriovenous fistula cannulation in haemodialysis children: efficacy of EMLA anaesthetic cream. Eur J Pain. 1998;2:109\u201313.","journal-title":"Eur J Pain"},{"key":"980_CR158","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7150\/ijms.8.623","volume":"8","author":"G \u00c7elik","year":"2011","unstructured":"\u00c7elik G, \u00d6zbek O, Yilmaz MM, Duman I, \u00d6zbek S, Apiliogullari S. Vapocoolant spray vs. lidocaine\/prilocaine cream for reducing the pain of venipuncture in hemodialysis patients: a randomized, placebo-controlled crossover study. Int J Med Sci. 2011;8:623\u20137.","journal-title":"Int J Med Sci."},{"key":"980_CR159","doi-asserted-by":"crossref","first-page":"955","DOI":"10.23736\/S0375-9393.18.12287-5","volume":"84","author":"JV Pergolizzi Jr","year":"2018","unstructured":"Pergolizzi JV Jr, Lequang JA, Taylor R Jr, Raffa RB, Colucci D, NEMA Research Group. The role of cannabinoids in pain control: the good, the bad, and the ugly. Minerva Anestesiol. 2018;84:955\u201369.","journal-title":"Minerva Anestesiol"},{"key":"980_CR160","doi-asserted-by":"crossref","first-page":"893","DOI":"10.23736\/S0375-9393.18.12701-5","volume":"84","author":"F Coluzzi","year":"2018","unstructured":"Coluzzi F. Cannabinoids in chronic pain management: a skein to be untangled. Minerva Anestesiol. 2018;84:893\u20135.","journal-title":"Minerva Anestesiol"},{"key":"980_CR161","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.ajkd.2017.06.020","volume":"71","author":"JL Rein","year":"2018","unstructured":"Rein JL, Wyatt CM. Marijuana and cannabinoids in ESRD and earlier stages of CKD. Am J Kidney Dis. 2018;71:267\u201374.","journal-title":"Am J Kidney Dis"},{"key":"980_CR162","first-page":"9035193","volume":"2017","author":"NC Chen","year":"2017","unstructured":"Chen NC, Hsu CY, Chen CL. The strategy to prevent and regress the vascular calcification in dialysis patients. Biomed Res Int. 2017;2017:9035193.","journal-title":"Biomed Res Int"},{"key":"980_CR163","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.02550508","volume":"4","author":"ND Toussaint","year":"2009","unstructured":"Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol. 2009;4:221\u201333.","journal-title":"Clin J Am Soc Nephrol"},{"key":"980_CR164","first-page":"97","volume":"13","author":"C Mattia","year":"2016","unstructured":"Mattia C, Coluzzi F, Celidonio L, Vellucci R. Bone pain mechanism in osteoporosis: a narrative review. Clin Cases Miner Bone Metab. 2016;13:97\u2013100.","journal-title":"Clin Cases Miner Bone Metab."},{"key":"980_CR165","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.ajkd.2012.06.019","volume":"60","author":"BB Mccormick","year":"2012","unstructured":"Mccormick BB, Davis J, Burns KD. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis. 2012;60:626\u20138.","journal-title":"Am J Kidney Dis"},{"key":"980_CR166","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13730-017-0254-5","volume":"6","author":"A Uehara","year":"2017","unstructured":"Uehara A, Yazawa M, Kawata A, Hachisuka R, Shibagaki Y. Denosumab for treatment of immobilization-related hypercalcemia in a patient with end-stage renal disease. CEN Case Rep. 2017;6:111\u20134.","journal-title":"CEN Case Rep."},{"key":"980_CR167","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2147\/JPR.S47192","volume":"6","author":"PK Morley-Forster","year":"2013","unstructured":"Morley-Forster PK, Pergolizzi JV, Taylor R Jr, Axford-Gatley RA, Sellers EM. Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum. J Pain Res. 2013;6:791\u2013801.","journal-title":"J Pain Res."},{"key":"980_CR168","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.pmn.2015.03.004","volume":"16","author":"S Zyga","year":"2015","unstructured":"Zyga S, Alikari V, Sachlas A, Stathoulis J, Aroni A, Theofilou P, et al. Management of pain and quality of life in patients with chronic kidney disease undergoing hemodialysis. Pain Manag Nurs. 2015;16:712\u201320.","journal-title":"Pain Manag Nurs."},{"key":"980_CR169","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2215\/CJN.00600115","volume":"10","author":"SN Davison","year":"2015","unstructured":"Davison SN. Pain, analgesics, and safety in patients with CKD. Clin J Am Soc Nephrol. 2015;10:350\u20132.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0980-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0980-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0980-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T02:57:32Z","timestamp":1662001052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0980-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":169,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["980"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0980-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"11 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation or publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Flaminia Coluzzi has no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}